

Invitation Letter

Fidaxomicin versus Vancomycin for Clostridium difficile Infection in IBD

IBD National Study Group Meeting 2023

Dear ECCO National Representatives,
Dear IBD National Study Group Representatives,
Dear colleagues,

Patients with inflammatory bowel disease (IBD) have an increased risk of Clostridium difficile Infection (CDI) with atypical clinical features. IBD patients with CDI are more likely to experience IBD exacerbations that necessitate escalation of therapy, emergency department visits, longer hospital admissions, and a higher risk of colectomy and mortality. All symptomatic IBD patients with confirmed CDI by stool testing should receive appropriate antimicrobial therapy, which is guided by data from the general population. In particular, data on fidaxomicin in IBD are very limited, mostly from small single-center studies.

With this email, the IBD team of the Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico of Milan (Italy) would like to ask different European IBD centres to collaborate on this topic through a multicenter retrospective cohort study. The aim of this study is to assess long-term outcomes, predictors of efficacy, and safety of fidaxomicin in a large cohort of IBD patients.

Each participating center will be requested to retrospectively collect data on IBD patients with CDI treated with fidaxomicin. The final version of the study protocol (see attached) has been reviewed by the Clinical Committee (ClinCom) of ECCO.

Who can collaborate?

- IBD centres with the possibility to retrieve data on IBD patients with CDI treated with fidaxomicin.
- IBD centres who are willing to fill out an electronic clinical research form (eCRF) through REDCap® software for all included patients.

If you are interested in collaborating on this study, please contact flavio.caprioli@unimi.it and daniele.noviello@unimi.it by October 25th, 2023. Please also forward this email to other IBD centers in your country.

We will aim for the submission of an abstract (with initial data) for ECCO 2024 and a full manuscript shortly thereafter. The publication list will take into account the number of patients included in the study.

We truly hope that this study will lead to a successful collaboration.

Sincerely,
Flavio Caprioli and Daniele Noviello